Altimmune and UAB to develop intranasal vaccine

30 March 2020 (Last Updated March 30th, 2020 14:48)

Biopharmaceutical firm Altimmune has partnered with the University of Alabama at Birmingham (UAB) to develop a Covid-19 vaccine for intranasal administration.

AdCOVID, the vaccine candidate, will be a single-dose formulation. Altimmune has already created the candidate and is working towards immunogenicity studies.

The company is also preparing to produce Phase I clinical trial material.

Read the full article here